Acute myeloid leukemia (AML) is rapidly fatal, poorly controlled disease that can be rapidly brought into complete remission but where relapse kills the vast majority of patients. The genetic evolution of the disease has been defined retrospectively, but the basis for resistance to therapy and effective strategies to overcome it are lacking. This project seeks to take advantage of well-defined mouse models where a human leukemogenic allele induces highly penetrant, lethal AML that can be temporarily brought into remission by chemotherapy agents used in patients. Combining these basic biologic features with novel strategies for quantitatively assessing clonal behavior, clonal molecular features, physical localization and the in vivo parameters of growth pathway, cell cycle and apoptosis over time will provide multidimensional datasets for mathematical modeling of the parameters correlating with: 1. Clonal dominance in vivo (Specific Aim 1) and, 2. Sensitivity/resistance to chemotherapy in vivo (Specific Aim 2). The models will guide experimental testing of the role of the parameters in the in vivo behavior of the disease that will then be used to develop and test methods for enhancing durable control of AML (Specific Aim 3).

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-TCRB-5)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
Independent Hospitals
United States
Zip Code
Gil Del Alcazar, Carlos R; Huh, Sung Jin; Ekram, Muhammad B et al. (2017) Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. Cancer Discov 7:1098-1115
Chakrabarti, Shaon; Michor, Franziska (2017) Pharmacokinetics and Drug Interactions Determine Optimum Combination Strategies in Computational Models of Cancer Evolution. Cancer Res 77:3908-3921
Peinado, H├ęctor; Zhang, Haiying; Matei, Irina R et al. (2017) Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer 17:302-317
Yu, H A; Sima, C; Feldman, D et al. (2017) Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. Ann Oncol 28:278-284
Smith, Zachary D; Shi, Jiantao; Gu, Hongcang et al. (2017) Epigenetic restriction of extraembryonic lineages mirrors the somatic transition to cancer. Nature 549:543-547
Temko, Daniel; Cheng, Yu-Kang; Polyak, Kornelia et al. (2017) Mathematical Modeling Links Pregnancy-Associated Changes and Breast Cancer Risk. Cancer Res 77:2800-2809
Dasgupta, Arko; Lim, Andrea R; Ghajar, Cyrus M (2017) Circulating and disseminated tumor cells: harbingers or initiators of metastasis? Mol Oncol 11:40-61
Jayatilaka, Hasini; Tyle, Pranay; Chen, Jonathan J et al. (2017) Synergistic IL-6 and IL-8 paracrine signalling pathway infers a strategy to inhibit tumour cell migration. Nat Commun 8:15584
Yu, Vionnie W C; Yusuf, Rushdia Z; Oki, Toshihiko et al. (2017) Epigenetic Memory Underlies Cell-Autonomous Heterogeneous Behavior of Hematopoietic Stem Cells. Cell 168:944-945
Smith, Kyle S; Liu, Lin L; Ganesan, Shridar et al. (2017) Nuclear topology modulates the mutational landscapes of cancer genomes. Nat Struct Mol Biol 24:1000-1006

Showing the most recent 10 out of 19 publications